The APAC epirubicin market is expected to grow from US$ 29,679.40 thousand in 2022 to US$ 37,447.28 thousand by 2028; it is estimated to grow at a CAGR of 4.0% from 2022 to 2028.
Rising Prevalence of Cancer Boosts Epirubicin Market
Epirubicin is an anthracycline drug that is used to treat breast cancer, stomach cancers, etc. It reduces the risk of relapse by attacking any remaining tumor cells after surgery or radiation therapy. Further, the number of people diagnosed with liver cancer has been rising, and it is common in several parts of the region. Hence, the rising prevalence of cancer cases is driving the epirubicin market across the region.
Market Overview
The APAC epirubicin market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. The developing economies such as China, India, and Indonesia are investing substantially in infrastructure and industrial development. In APAC, China is the largest market for epirubicin. The market growth is primarily attributed to the growing pharmaceutical industry, increasing developments by the market players, and favorable regulatory policies. Further, the excessive population in China and the rising prevalence of cancer are majorly boosting the demand for cancer drugs. Also, the growing prevalence of cancer in China is likely to increase the demand for cancer treatment. As per the WHO report, in 2020, there were ~4,568,754 new cases of cancer and 3,002,899 cancer-associated deaths in China. Thus, the huge cancer patient population and product and treatment developments by the market players are expected to propel the demand for cancer vaccines in the country.
APAC Epirubicin Market Revenue and Forecast to 2028 (US$ Thousand)
APAC Epirubicin Market Segmentation
The APAC epirubicin market is segmented based on dosage, application, distribution channel, and country
Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Miracalus Pharma Pvt. Ltd., Mylan N.V., Pfizer Inc., Salius Pharma Pvt Ltd, and Teva Pharmaceutical Industries Ltd. are the leading companies operating in the APAC epirubicin market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 29,679.40 thousand |
| Market Size by 2028 | US$ 37,447.28 thousand |
| CAGR (2022 - 2028) | 4.0% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Dosage
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia-Pacific Epirubicin Market is valued at US$ 29,679.40 thousand in 2022, it is projected to reach US$ 37,447.28 thousand by 2028.
As per our report Asia-Pacific Epirubicin Market, the market size is valued at US$ 29,679.40 thousand in 2022, projecting it to reach US$ 37,447.28 thousand by 2028. This translates to a CAGR of approximately 4.0% during the forecast period.
The Asia-Pacific Epirubicin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia-Pacific Epirubicin Market report:
The Asia-Pacific Epirubicin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia-Pacific Epirubicin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia-Pacific Epirubicin Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia-Pacific Epirubicin Market
